Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06073574 · ClinicalTrials.gov registry record
CARDIO-TTRansform Magnetic Resonance Imaging (MRI) Sub-study
A clinical trial of Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM), sponsored by Ionis Pharmaceuticals.
- Active
- Registry status
- 150
- Enrollment target
- 11
- Study locations
NCT06073574: Active study of Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM), sponsored by Ionis Pharmaceuticals.
NCT06073574 is a study of Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) that is active but no longer recruiting, run by Ionis Pharmaceuticals. The registered enrollment target is 150 participants. The trial reports 11 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06073574, a study of Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM), is active but no longer recruiting, sponsored by Ionis Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- 150 participants
- Enrollment target
- 11
- Study locations
Study Summary
The main purpose of this study is to measure the amyloid burden, defined as extracellular volume (ECV) assessed by Magnetic Resonance Imaging (MRI) over time in a subset of up to 150 participants enrolled in ION-682884-CS2 (NCT04136171).
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Cardiac MRI
Study Locations (11)
Other
- Azienda Ospedaliero - Universitaria Careggi - Florence
- Azienda Ospedale Università di Padova - Padua
- Hospital Universitario Puerta de Hierro - Majadahonda
- Synexus - Scotland Clinical Research Centre - Bellshill
- Synexus Midlands Clinical Research Centre - Birmingham
- Synexus - Wales - Cardiff
- Royal Free London NHS Foundation Trust - London
- Richmond Pharmacology - London
- Synexus - Manchester Clinical Research Centre - Manchester
Massachusetts
- Brigham and Women's Hospital - Boston
Oregon
- Oregon Health and Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2021-03-31 |
| Est. Completion | 2026-04 |
What the registry record for NCT06073574 still lists
NCT06073574 is an observational study that tracks outcomes without assigning an intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) appearing as the primary indexed condition, and to 1 intervention - of which Cardiac MRI is the first listed.
NCT06073574 lists 11 locations in 3 states (Other, Massachusetts, Oregon).
Frequently Asked Questions
What is clinical trial NCT06073574 about?
NCT06073574 is a clinical study titled "CARDIO-TTRansform Magnetic Resonance Imaging (MRI) Sub-study". The main purpose of this study is to measure the amyloid burden, defined as extracellular volume (ECV) assessed by Magnetic Resonance Imaging (MRI) over time in a subset of up to 150 participants enrolled in ION-682884-CS2 (NCT04136171).
What is the current status of trial NCT06073574?
This trial is currently active not recruiting. The enrollment target is 150 participants. The study started on 2021-03-31. Estimated completion is 2026-04.
What conditions does trial NCT06073574 study?
This clinical trial studies the following conditions: Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM).
What interventions are being tested in trial NCT06073574?
The interventions under investigation include: Cardiac MRI (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06073574?
This trial is sponsored by Ionis Pharmaceuticals, which has 76 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06073574 being conducted?
This trial has 11 study locations across Massachusetts, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
ACTIVE NOT RECRUITING · Phase 3
-
The CARDIO-TTRansform Scintigraphy Sub-study
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI